Complement control for COVID-19

Sci Immunol. 2021 May 25;6(59):eabj1014. doi: 10.1126/sciimmunol.abj1014.

Abstract

Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related Research Articles by Yan et al and Ma et al).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • COVID-19*
  • Complement Activation
  • Complement System Proteins
  • Humans
  • SARS-CoV-2*

Substances

  • Complement System Proteins